Is HUMA or IBRX more undervalued in 2026?

CirclFi compares Humacyte, Inc. (HUMA) and ImmunityBio, Inc. (IBRX) using 13 institutional-grade valuation models. HUMA has a Quality of Company score of 3.5/10 while IBRX scores 5.9/10.

Which is a better buy — HUMA or IBRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HUMA and IBRX valuations compare?

HUMA at $1.28 and IBRX at $7.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HUMA vs IBRX Valuation Comparison 2026 — Intrinsic Value Analysis

HUMA

Biotechnology

Humacyte, Inc.

Quality

3.5

out of 10

Value Trap

LOW

Price

$1.28

Last close

Models

5/13

Active

IBRX

Biotechnology

ImmunityBio, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$7.72

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	HUMA Fair Value	HUMA Upside	IBRX Fair Value	IBRX Upside
Bayesian DCF	Intrinsic	$0.35	-73.0%	$1.07	-86.1%
Earnings Power Value	Intrinsic	—	—	$0.54	-92.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.36	-72.2%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HUMA vs IBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HUMA vs IBRX — Which Stock Is More Undervalued?

IBRX scores higher with a 5.9/10 quality rating vs HUMA's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Humacyte, Inc. (HUMA) and ImmunityBio, Inc. (IBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HUMA currently trades at $1.28 with a QOC of 3.5/10, while IBRX trades at $7.72 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).